- Home
- SCLX vs ATRA Comparison
SCLX vs ATRA Comparison
Compare SCLX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- ATRA
- Stock Information
- Founded
- SCLX 2011
- ATRA 2012
- Country
- SCLX United States
- ATRA United States
- Employees
- SCLX N/A
- ATRA N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCLX Health Care
- ATRA Health Care
- Exchange
- SCLX Nasdaq
- ATRA Nasdaq
- Market Cap
- SCLX 72.5M
- ATRA 65.1M
- IPO Year
- SCLX N/A
- ATRA 2014
- Fundamental
- Price
- SCLX $0.45
- ATRA $6.57
- Analyst Decision
- SCLX Strong Buy
- ATRA Buy
- Analyst Count
- SCLX 3
- ATRA 6
- Target Price
- SCLX $11.33
- ATRA $25.70
- AVG Volume (30 Days)
- SCLX 184.3K
- ATRA 306.8K
- Earning Date
- SCLX 03-11-2025
- ATRA 11-12-2024
- Dividend Yield
- SCLX N/A
- ATRA N/A
- EPS Growth
- SCLX N/A
- ATRA N/A
- EPS
- SCLX N/A
- ATRA N/A
- Revenue
- SCLX $55,152,000.00
- ATRA $100,439,000.00
- Revenue This Year
- SCLX $32.77
- ATRA $1,339.87
- Revenue Next Year
- SCLX $50.71
- ATRA N/A
- P/E Ratio
- SCLX N/A
- ATRA N/A
- Revenue Growth
- SCLX 9.41
- ATRA 2111.34
- 52 Week Low
- SCLX $0.38
- ATRA $6.50
- 52 Week High
- SCLX $2.63
- ATRA $39.50
- Technical
- Relative Strength Index (RSI)
- SCLX 42.08
- ATRA 32.06
- Support Level
- SCLX $0.40
- ATRA $6.55
- Resistance Level
- SCLX $0.53
- ATRA $17.83
- Average True Range (ATR)
- SCLX 0.05
- ATRA 2.21
- MACD
- SCLX 0.01
- ATRA -0.91
- Stochastic Oscillator
- SCLX 47.59
- ATRA 0.16
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).